AstraZeneca PLC (AZN) Stock Analysis

Company Overview

AstraZeneca PLC operates as a biopharmaceutical entity dedicated to the discovery, development, manufacture, and commercialization of prescription medicines. The company functions within the healthcare sector, specifically the drug manufacturers-general industry, positioning it as a key player in the pharmaceutical landscape. With a market capitalization of $292.10B, annual revenue of $58.74B, and an employee count of 96100, AstraZeneca PLC demonstrates a massive operational scale that places it among the largest entities in its field. These substantial market cap and revenue figures indicate that the company holds a significant position in the global pharmaceutical market, commanding considerable resources and market influence relative to smaller peers in the drug manufacturing industry.

Financial Health

The company reported revenue of $58.74B, net income of $10.23B, and EBITDA of $19.28B for the trailing twelve months. The substantial gap between the $58.74B revenue and the $10.23B net income reveals a robust cost structure where operating expenses and taxes account for approximately 82.6% of total revenue, reflecting the high fixed costs typical of large-scale drug manufacturing. AstraZeneca PLC generated free cash flow of $7.87B, which provides significant financial flexibility to fund research and development initiatives, manage capital expenditures, or pursue strategic acquisitions without needing to dilute shareholders immediately. Profitability is supported by a gross margin of 81.7%, indicating high pricing power and efficiency in production; an operating margin of 21.6% shows effective control over overhead and administrative costs; and a profit margin of 17.4% confirms strong bottom-line performance. The balance sheet shows $5.72B in cash against $29.70B in debt, resulting in a debt-to-equity ratio of 60.97, which suggests a leveraged balance sheet reliant on financing to support operations. However, the current ratio of 0.94 indicates that current assets are slightly lower than current liabilities, suggesting a need to monitor short-term liquidity carefully to meet immediate obligations. Management effectiveness is highlighted by a return on equity of 22.8%, demonstrating efficient use of shareholder capital, while a return on assets of 8.2% reflects the overall efficiency of asset deployment across the entire organization.

Valuation Assessment

The trailing twelve-month P/E ratio stands at 28.81, while the forward P/E is 31.57, implying that the market expects earnings to grow faster than current levels to justify the higher multiple in the future. The price-to-book ratio of 6.00 indicates that the market values the company at six times its book value, reflecting a significant premium assigned to its intangible assets, brand strength, and future growth prospects rather than just its tangible assets. Alternative valuation metrics such as a price-to-sales ratio of 4.97 and an EV/EBITDA of 16.40 suggest that investors are willing to pay a premium for revenue and earnings stability compared to the broader market average. The stock has traded between a 52-week low of $122.48 and a 52-week high of $212.71, meaning the current price sits within a wide trading range that encompasses both significant downside protection and substantial upside potential relative to recent lows. With a beta of 0.23, the stock exhibits low price volatility relative to the broader market, indicating that its price movements are generally less sensitive to overall market fluctuations, which may appeal to income-focused investors seeking stability.

Growth & Income

Revenue growth for the year-over-year period is 4.1%, while earnings growth is significantly higher at 53.9%, implying that cost efficiencies, margin expansion, or strategic portfolio shifts are driving profitability at a much faster pace than top-line sales. As a dividend payer, AstraZeneca PLC offers a dividend yield of 1.7% with a payout ratio of 47.9%, suggesting that the dividend is sustainable given the strong earnings growth and healthy free cash flow generation which supports consistent payouts without compromising reinvestment needs. The high earnings growth relative to revenue suggests the company is successfully optimizing its existing assets or launching high-margin products that disproportionately contribute to the bottom line. Overall, the company presents a growth and income profile characterized by accelerating profitability, a sustainable dividend policy, and a valuation that balances current earnings with future growth expectations.